COVID-19 vaccine: Zydus Cadila gets DGCI nod for phase 3 clinical trials of Pegylated Interferon Alpha-2
https://ift.tt/3muub1k
Drug firm Zydus Cadila on Friday said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
Drug firm Zydus Cadila on Friday said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
No comments